- Home
- DXLG vs IPSC Comparison
DXLG vs IPSC Comparison
Compare DXLG & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | IPSC |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 47.6M |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXLG | IPSC |
|---|---|---|
| Price | $1.14 | $0.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $3.00 |
| AVG Volume (30 Days) | 70.8K | ★ 979.5K |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4122.69 |
| 52 Week Low | $0.88 | $0.34 |
| 52 Week High | $3.10 | $1.74 |
Technical Indicators
Market Signals| Indicator | DXLG | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 48.66 |
| Support Level | $0.90 | $0.50 |
| Resistance Level | $1.00 | $0.54 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.29 | 74.26 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.